MADRIGAL PHARMACEUTICALS INC (MDGL) Earnings History & Surprises
NASDAQ:MDGL • US5588681057
432.83 USD
-6.51 (-1.48%)
At close: Mar 6, 2026
430.3 USD
-2.53 (-0.58%)
After Hours: 3/6/2026, 8:00:02 PM
Past quarterly earnings results for MADRIGAL PHARMACEUTICALS INC (MDGL), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Release DateApr 29, 2026
PeriodQ1 / 2026
EPS Estimate-$3.39
Revenue Estimate309.16M
Last Reported
Release DateFeb 19, 2026
PeriodQ4 / 2025
EPS Reported-$2.57
EPS Surprise -274.00%
Revenue Surprise 0.74%
Beat Rate
31%
EPS and Revenuebeats vs estimates
Quarterly Earnings Results
EPS & Revenue History (USD)
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -2.57 | -0.69 | -274.00% | 5.17% | 321.083M | 318.74M | 0.74% | 210.77% |
| Q3 2025 | -4.96 | -2.12 | -133.61% | -0.81% | 287.268M | 252.25M | 13.88% | 362.03% |
| Q2 2025 | -1.90 | -3.71 | 48.79% | 73.24% | 212.802M | 165.56M | 28.53% | 1,353.76% |
| Q1 2025 | -3.32 | -3.84 | 13.46% | 55.01% | 137.25M | 116.1M | 18.22% | - |
| Q4 2024 | -2.71 | -4.33 | 37.40% | 52.29% | 103.32M | 100.53M | 2.78% | - |
| Q3 2024 | -4.92 | -7.05 | 30.22% | 7.87% | 62.175M | 34.873M | 78.29% | - |
| Q2 2024 | -7.10 | -7.68 | 7.50% | -51.39% | 14.638M | 3.981M | 267.70% | - |
| Q1 2024 | -7.38 | -6.41 | -15.12% | -74.47% | - | - | ||
| Q4 2023 | -5.68 | -5.39 | -5.38% | -14.06% | - | - | ||
| Q3 2023 | -5.34 | -5.02 | -6.30% | -12.42% | - | - | ||
| Q2 2023 | -4.69 | -4.67 | -0.37% | -13.29% | - | - | ||
| Q1 2023 | -4.23 | -5.04 | 16.00% | -25.89% | - | - | ||
| Q4 2022 | -4.98 | -4.65 | -7.16% | -31.75% | - | - | ||
| Q3 2022 | -4.75 | -4.24 | -12.11% | -25.33% | - | - | ||
| Q2 2022 | -4.14 | -3.77 | -9.78% | -11.29% | - | - | ||
| Q1 2022 | -3.36 | -3.69 | 9.02% | -1.20% | - | - | ||
| Q4 2021 | -3.78 | -3.95 | 4.41% | 1.05% | - | - | ||
| Q3 2021 | -3.79 | -3.98 | 4.67% | -1.07% | - | - | ||
| Q2 2021 | -3.72 | -3.66 | -1.75% | -16.98% | - | - | ||
| Q1 2021 | -3.32 | -3.92 | 15.32% | -41.88% | - | - | ||
| Q4 2020 | -3.82 | -3.93 | 2.85% | - | - | - | ||
| Q3 2020 | -3.75 | -3.36 | -11.47% | - | - | - | ||
| Q2 2020 | -3.18 | -2.50 | -27.07% | - | - | - | ||
| Q1 2020 | -2.34 | -1.98 | -18.07% | - | - | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
2
Average EPS beat (4)
-86.34%
Max EPS beat (4)
48.79%
Min EPS beat (4)
-274.00%
Revenue beat statistics
Revenue beat (4)
4
Average Revenue beat (4)
15.34%
Max Revenue beat (4)
28.53%
Min Revenue beat (4)
0.74%
Analysis
In the last 4 quarters, MDGL has beaten EPS estimates in 2 out of 4 releases
MDGL has consistently beaten revenue estimates in all past 4 earnings releases
In the last 4 quarters, MDGL reported -86.3% below the EPS estimates on average.
In the last 4 quarters, MDGL has beaten the revenue estimates by 15.3% on average.
MADRIGAL PHARMACEUTICALS INC / MDGL Earnings FAQ
When did MADRIGAL PHARMACEUTICALS INC (MDGL) report earnings last quarter?
MADRIGAL PHARMACEUTICALS INC (MDGL) last reported earnings on 2/19/2026.
Did MDGL stock beat earnings estimates in the most recent quarter?
MADRIGAL PHARMACEUTICALS INC (MDGL) missed EPS estimates and beat revenue estimates in the most recent quarter.
Can you provide information on how often MADRIGAL PHARMACEUTICALS INC beats earnings estimates?
In the last 4 quarters, MADRIGAL PHARMACEUTICALS INC (MDGL) has beaten EPS estimates in 2 out of 4 releases.